Translational Research

• Debate: NGS Testing for All Patients With GI Cancers? - Not Yet
• Debate: NGS Testing for All Patients With GI Cancers? - Yes
• DNA Repair Mechanisms and Pathways
• Fusions in GI Cancer
• Keynote Lecture: The Microbiome in GI Cancer: How Relevant is it?
• 001 - NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND
• EB16 - CAR T CELL THERAPY: FULL SPEED AHEAD
• Expert video report on Targeting NTRK gene fusions across cancers
• Understanding the biology of TNBC: Where are we in 2019?
• miRNA expression profiles in BRCA1-associated breast cancers reveal upregulation of specific miRNAs in tumors lacking a clear second hit in a large...
• The mutational profile of IBC reveals higher mutational burden, deficiency of homologous recombination and NOTCH signalling
• Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling
• Pro
• Contra
• What is different in the biology of Inflammatory Breast Cancer?
• Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)
• Hereditary breast cancer and PARP inhibitors
• Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling
• Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer
• Investigation on the MyD88 mediated TLR3 signaling via cell surface in breast cancer
• Association of serum IGF1 and adiponectin in prognosis of breast cancer metastasis
• Regulation of MMP9 expression by human arylamine N-acetyltransferase (NAT1) via Hif-1a
• CD146 suppresses breast tumor via its novel downstream signaling pathway, Latexin/Akt/NFκB
• Sensitivity and dynamic range of CellSearch based CSF DTC enumeration in patients with breast cancer related leptomeningeal metastases (LM)
• Heterozygous mutation in fanconi anemia genes associated with hereditary breast cancer

• « Previous
• 1
• 2
• ...
• 115
• Next »